Details for New Drug Application (NDA): 062666
✉ Email this page to a colleague
NDA 062666 describes CEPHALOTHIN SODIUM, which is a drug marketed by Abbott, Abraxis Pharm, Bristol, and Baxter Hlthcare, and is included in six NDAs. Additional details are available on the CEPHALOTHIN SODIUM profile page.
The generic ingredient in CEPHALOTHIN SODIUM is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
The generic ingredient in CEPHALOTHIN SODIUM is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
Summary for 062666
| Tradename: | CEPHALOTHIN SODIUM |
| Applicant: | Abraxis Pharm |
| Ingredient: | cephalothin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062666
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Jun 10, 1987 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Jun 10, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
